Maze Therapeutics, Inc. (MAZE) vs The Pennant Group, Inc. (PNTG)
A side-by-side comparison of Maze Therapeutics, Inc. and The Pennant Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MAZE
Maze Therapeutics, Inc.
$26.19HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
PNTG
The Pennant Group, Inc.
$40.45HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Total return — MAZE vs PNTG
growth of $100 · dividends reinvested · last 2yMAZE +65.7% (+28.7%/yr)PNTG +46.7% (+21.1%/yr)MAZE compounded faster over this window
MAZE PNTG
MAZE vs PNTG: by the numbers
- •MAZE is the larger company ($1.45B vs $1.41B market cap).
- •PNTG is profitable (2.93% net margin) while MAZE runs a net loss (-667.95%).
Metrics side by side
Valuation
| Metric | MAZE | PNTG |
|---|---|---|
| P/E ratio | N/A | 44.95 |
| Forward P/E | N/A | 28.98 |
| PEG ratio | N/A | 4.46 |
| P/S ratio | 72.47 | 1.28 |
| P/B ratio | 3.20 | 3.92 |
| EV / EBITDA | N/A | 25.58 |
| FCF yield | N/A | 1.85% |
Profitability
| Metric | MAZE | PNTG |
|---|---|---|
| Gross margin | 0.00% | 14.79% |
| Operating margin | 0.00% | 5.77% |
| Net margin | -667.95% | 2.93% |
| ROE | -29.48% | 9.00% |
| ROIC | -28.63% | 5.22% |
Growth (annualized)
| Metric | MAZE | PNTG |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 21.14% |
| EPS CAGR (5Y) | N/A | 8.96% |
| Total return CAGR (5Y) | N/A | 8.88% |
Frequently asked
- Is MAZE or PNTG more profitable?
- PNTG runs the higher net margin — MAZE at -667.95% versus PNTG at 2.93%.
Go deeper
Dig into the metrics
Pennant P/E ratioMaze Therapeutics ROEPennant ROEMaze Therapeutics operating marginPennant operating marginMaze Therapeutics revenue growthPennant revenue growthMaze Therapeutics free cash flowPennant free cash flow
Maze Therapeutics & Pennant appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.